FDA approvals: Orzeyful, Tudriqev and mFLUSIVA lead the Aug. 1–7 ledger (2026)

At a glance

The FDA record for July 31 at 5:00 p.m. through August 7 at 5:00 p.m. UTC-05:00 is led by three drug and biologic actions: Takeda’s Orzeyful for adult narcolepsy type 1, Replimune’s accelerated approval of Tudriqev plus nivolumab for PD-1-refractory advanced cutaneous melanoma, and Moderna’s mFLUSIVA influenza vaccine for adults 50 and older. A Yescarta supplement adds a cerebral-edema warning for a defined lymphoma population; it is a safety-label change, not a new indication.

The device ledger needs a separate reading. FDA’s public 510(k) final-decisions page was updated August 3, while the downloadable 510(k) and PMA files captured for this issue contain decisions only through July 31. They show no new August 1–7 device decisions in the captured official files. Three companies separately announced 510(k) clearances during the week; those items are listed below as a company-announced watchlist, not silently merged into the FDA ledger.

Action	Date	Population or use	Immediate read
Orzeyful (oveporexton) — Takeda	Aug. 5	Adults with narcolepsy type 1	First U.S. approved orexin therapy aimed at the underlying disorder; launch awaits DEA scheduling. 1
Tudriqev (vusolimogene oderparepvec-wtpg) — Replimune	Aug. 6	Adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking regimen	Accelerated approval based on response rate and response duration; confirmatory overall-survival trial remains the regulatory hinge. 2
mFLUSIVA (mRNA-1010) — ModernaTX	Aug. 5	Adults 50 and older; age 65+ under accelerated approval	First FDA-approved mRNA influenza vaccine; the older-adult benefit still needs postmarketing confirmation. 3
YESCARTA supplement — Kite Pharma	Aug. 6	Patients with primary mediastinal B-cell lymphoma	Label revisions increase the cerebral-edema warning; no new disease indication. 4

New drug approvals and indication

Orzeyful: a new mechanism, with access still outside the FDA’s control

FDA approved oral Orzeyful (oveporexton) for adults with narcolepsy type 1, the form of narcolepsy associated with cataplexy. The drug is an orexin receptor 2 agonist: it is designed to activate the receptor normally stimulated by orexin, the signaling deficit implicated in type 1 disease. FDA describes the approval as the first medicine intended to treat the full range of NT1 symptoms rather than one symptom at a time. 1

Takeda based the application on the Phase 3 FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies. The company reported statistically significant improvements in excessive daytime sleepiness, cataplexy, and health-related quality of life. The label and company safety information call out insomnia, urinary frequency, urinary urgency, and salivary hypersecretion; Orzeyful is contraindicated with strong CYP3A inhibitors, and Takeda advises against use in severe hepatic impairment or severe renal impairment on dialysis. 5

Commercial read. Takeda estimates that about 120,000 people in the United States have NT1. The competitive field is the existing symptom-management stack; Takeda’s announcement does not provide a named-product market-share estimate or a U.S. price. The product is expected to reach patients through a specialty pharmacy only after the DEA completes controlled-substance scheduling, which Takeda said it expected within 90 days of the announcement. The company also said the approval was not expected to have a significant effect on its consolidated financial forecast for the fiscal year ending March 31, 2027. 5

For clinicians, the practical question is whether a disease-directed mechanism changes symptom control without making insomnia and urinary adverse effects unacceptable. For investors, the first milestones are not the approval headline but DEA scheduling, specialty-pharmacy availability, payer access, and the pace at which a 120,000-person rare-disease pool converts into treated patients.

Tudriqev: a response-based approval that now has to earn permanence

FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), Replimune’s genetically modified oncolytic viral therapy, for use with nivolumab in adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD-1-blocking antibody-based regimen. The indication is narrower than the full melanoma market: it is a post-checkpoint setting, not a first-line approval. 6

The approval rests on IGNYTE (NCT03767348), an open-label, multiregional, single-arm trial. Of 140 enrolled patients, 91 with at least one noninjected lesion formed the efficacy-evaluable group. Objective response rate was 24.2% (95% confidence interval, 15.8%–34.3%), and median duration of response was 14.1 months (95% confidence interval, 10.7 months to not reached). Serious adverse reactions occurred in 35% of the 140 patients; adverse reactions leading to permanent discontinuation occurred in 2.9%. The FDA label highlights accidental exposure, herpetic infection or reactivation, injection-procedure complications, and immune-mediated events. 2

This is also a treatment-delivery story. Tudriqev is injected directly into tumors; deep or visceral lesions require image guidance. That creates a different operational burden from an infused checkpoint inhibitor and makes referral pathways, imaging capacity, and experience with intratumoral administration part of the launch equation. Replimune says its ReplimuneConnect Plus program will provide access, reimbursement, and financial-support information, but the company has not disclosed a product price in the materials reviewed. 7

Commercial read. Replimune’s release cites an estimated 105,000 new U.S. melanoma cases in 2025 and nearly 8,500 annual deaths, but the addressable population for this label is the smaller PD-1-refractory advanced group. The company says more than half of patients progress within six months on checkpoint inhibitors and that median overall survival after progression is less than one year. BMO Capital Markets, as reported by BioSpace, models $1.3 billion in peak revenue in 2035; that is an analyst estimate, not company guidance or FDA evidence. 8

The regulatory risk is explicit. FDA requires Replimune to complete IGNYTE-3 (RP1-104; NCT06264180), a randomized Phase 3 trial of about 400 patients with overall survival as the primary endpoint. The final protocol is due August 31, 2026, trial completion is scheduled for September 2030, and the final report is due March 2031. Continued approval may depend on verification and description of clinical benefit. 9

mFLUSIVA: broad seasonal reach, but a split regulatory standard by age

FDA approved ModernaTX’s mFLUSIVA (mRNA-1010) for active immunization against influenza A and B strains represented in the vaccine for people 50 and older. The 65-and-older indication was granted under accelerated approval; the 50–64 approval rests on the Phase 3 FLUENT program. 3

The Phase 3 study NCT06602024 enrolled 40,805 adults across 11 countries and compared mFLUSIVA with a standard-dose influenza vaccine. The FDA’s advisory material reports a 26.6% relative vaccine efficacy versus that comparator against RT-PCR-confirmed, protocol-defined influenza-like illness (95% confidence interval, 16.7%–35.4%). For the 65+ indication, Moderna submitted a separate U.S. study of 2,992 adults against a high-dose inactivated influenza vaccine comparator; the approval letter requires a postmarketing study, mRNA-1010-P910, to verify relative effectiveness in that population. 10

Commercial read. The label creates a large seasonal pool—U.S. adults 50 and older—but the approval materials do not provide a commercial denominator, price, or reimbursement forecast. The relevant competitors are already entrenched standard-dose products for adults 50–64 and high-dose products for older adults, exactly the comparators used in the clinical program. Moderna expects supply for the 2026–2027 respiratory-virus season and says doses should reach select retailers in the coming weeks. 11

The market question is not simply whether mRNA can produce a stronger immune response. It is whether a seasonal vaccine with a new platform can win recommendation, procurement, pharmacy shelf space, and repeat uptake against established products before the season begins. For clinicians, the age split matters: the older-adult indication still carries a confirmatory obligation, along with deferred pediatric studies and active safety surveillance. For patients, availability and coverage will matter more than the platform label.

Biologics supplement: a safety signal, not a new indication

YESCARTA: cerebral-edema warning added for primary mediastinal B-cell lymphoma

FDA’s August 6 supplement approval for Kite Pharma’s YESCARTA (axicabtagene ciloleucel) revises Sections 5, Warnings and Precautions, and 6, Adverse Reactions, to address an increased risk of cerebral edema in patients with primary mediastinal B-cell lymphoma. The letter does not create a new indication or expand the eligible population. 4

That makes this a clinically relevant label implementation item rather than a new commercial launch. Treatment centers should review the revised warning and monitoring language for the affected population. Investors should not count the action as incremental indication revenue without a separate label expansion.

Device ledger

What the official FDA files captured

The FDA 510(k) Final Decisions page reported a database update on August 3, 2026. The captured downloadable 510(k) file was also updated August 3 but contained decision dates only through July 31; the captured PMA file likewise had no decision date after July 31. The official 2026 supporting-documents page says its list is ordered by clearance date and reflects information available as of each clearance date, but it does not establish that no later agency decisions existed after the file capture. 12 13

Accordingly, this issue records no new August 1–7 510(k) or PMA decisions from the official downloadable ledger. The result is a captured-file statement, not a claim that FDA made no device decisions during the week.

Company-announced 510(k) clearances to verify when the FDA ledger catches up

These announcements fall inside the issue window and carry enough intended-use detail to matter to clinicians and investors. They remain separate from the official FDA file because the corresponding item-level records were not visible in the captured downloadable ledger.

Device and applicant	Company-announced date	Intended use and commercial signal
Revi Extend — BlueWind Medical	Aug. 5	510(k)-cleared implant for urgency urinary incontinence; the next-generation tibial neuromodulation implant is designed for a 15-year implant life. BlueWind plans a limited U.S. launch in Q4 2026. The announcement does not disclose price, reimbursement, or an addressable-patient estimate. 14
OMNI Ultra Surgical System — Sight Sciences	Aug. 4	510(k)-cleared handheld, single-use MIGS device for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adults with primary open-angle glaucoma; it can be used alone or with cataract surgery. U.S. launch is planned for Q4 2026. No price or revenue guidance was disclosed. 15
Concentriq AP-Dx — Proscia	Aug. 6	The new 510(k) clearance adds support for the Leica Aperio GT 450 DX scanner and authorizes a Predetermined Change Control Plan for adding other FDA-cleared whole-slide scanners, image formats, and pathology displays. The commercial value is workflow interoperability for primary diagnosis, not a new patient indication; price and market-size guidance were not disclosed. 16

The next verification step for all three is the FDA item-level record: decision number, official decision date, applicant, classification, and the precise cleared-use statement. Until then, company announcements should not be treated as a substitute for the agency’s own database.

Market reaction: useful signal, weak attribution

Daily closes around the approval dates show why the price tape should be treated as context rather than proof of an approval effect. In the market-data snapshot used for this issue, TAK closed at $16.72 on August 5 and $17.45 on August 7; REPL moved from $11.83 on August 5 to $12.86 on August 6, then $12.06 on August 7; MRNA moved from $56.26 on August 5 to $53.86 on August 6 and $59.17 on August 7. That is roughly +4.4%, +1.9%, and +5.2%, respectively, from each company’s approval-date close to Friday’s close, with sharp interim reversals for REPL and MRNA. 17 18 19

These moves cannot be assigned to the FDA actions alone: the window also includes earnings, broader biotech trading, and ordinary volatility. No independently verified analyst-rating change or institutional note was identified for this issue. The useful investor question is therefore whether launch evidence confirms the commercial assumptions above, not whether a two-day move proves them.

What matters next

Orzeyful: DEA scheduling, specialty-pharmacy launch, payer coverage, and early discontinuation rates will determine whether a 120,000-person prevalence estimate turns into a material treated population.
Tudriqev: Track IGNYTE-3 enrollment and protocol execution, overall-survival evidence, treatment-center capacity for image-guided intratumoral injection, and reimbursement support in the PD-1-refractory setting.
mFLUSIVA: Watch retailer availability for the 2026–2027 season, uptake versus standard-dose and high-dose comparators, and execution of the 65+ postmarketing effectiveness study.
YESCARTA: Treat the cerebral-edema revision as a safety-monitoring and label-implementation action for primary mediastinal B-cell lymphoma, not as a new indication.
Devices: Recheck the FDA 510(k) and PMA ledgers for the company-announced items and record the official decision numbers before treating them as fully verified weekly agency actions.